The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients
| Autor: | Vincent C. Marconi, Scott Wegner, Amy C. Weintrob, R. Vincent Barthel, Brian K. Agan, Mollie P. Roediger, Katherine Huppler Hullsiek, Nancy F. Crum-Cianflone, Anuradha Ganesan, Susan Fraser |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
Adult Male Risk medicine.medical_specialty Population HIV Infections Biology Article Cohort Studies Prostate cancer Internal medicine Antiretroviral Therapy Highly Active Neoplasms medicine Anticarcinogenic Agents Humans Pharmacology (medical) Adverse effect education Proportional Hazards Models Retrospective Studies education.field_of_study Nelfinavir Cancer HIV Protease Inhibitors medicine.disease Regimen Infectious Diseases Immunology Cancer cell Female Skin cancer medicine.drug |
| Zdroj: | Journal of acquired immune deficiency syndromes (1999). 51(3) |
| ISSN: | 1525-4135 |
| Popis: | Preclinical studies suggest that the antiretroviral agent, nelfinavir mesylate (NFV), may have antineoplastic properties. The relationship between NFV and cancer incidence among HIV-infected patients is unknown.We evaluated the impact of NFV on cancer development in a large cohort of HIV-infected persons with 108 cancer events during 13,421 person-years of follow-up. Using multivariate time-updated Cox proportional hazard models, the risk of cancer among those receiving NFV were compared to those on non-NFV antiretroviral regimens.The risk of cancer among those receiving NFV was similar to those on non-NFV antiretroviral regimens (hazard ratio 1.0, 95% confidence interval 0.5, 1.7, P = 0.90). We also examined AIDS-defining and non-AIDS-defining cancers separately and found no significant associations between NFV use and cancer risk. Antiretroviral use, with or without a protease inhibitor (PI) component, was associated with a reduced risk of AIDS-defining cancers compared with no antiretroviral therapy; however, the risk of cancer was the same among those using PI or PI-sparing regimens.Despite reports that NFV may have tumoricidal activity, we found no significant relationship between NFV or PI use compared with other antiretrovirals and the risk of developing cancer among a large cohort of HIV-infected persons. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|